← All trials
NCT06071624
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2043
- First posted
- Oct 6, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Indiana UniversityLead sponsor
- Indiana UniversityOverall official - principal investigator
- Indiana UniversitySponsor investigator
- The Leukemia and Lymphoma SocietyCollaborator
- iCell Gene TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.